Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) RegistryMaría Silvina Odstrcil Bobillo, Matthew J. Frigault, Swetha Kambhampati et al.|Blood|2024Cited by 7
Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) and Secondary Central Nervous System (sCNS) Involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) RegistrySairah Ahmed, Jennifer L. Crombie, Sagar S. Patel et al.|Blood|2024Cited by 6
CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World SettingBradley D. Hunter, Manali Kamdar, Matthew A. Lunning et al.|Transplantation and Cellular Therapy|2025Cited by 3
Outcomes of Standard of Care (SOC) Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) and Secondary CNS (sCNS) Involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) RegistrySairah Ahmed, Jennifer L. Crombie, Avyakta Kallam et al.|Transplantation and Cellular Therapy|2025Cited by 2
Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphomaJennifer L. Crombie, Iris Isufi, Sairah Ahmed et al.|Blood|2026Cited by 1